Literature DB >> 23345624

Improved survival among sickle cell kidney transplant recipients in the recent era.

Edmund Huang1, Chong Parke, Alireza Mehrnia, Mandana Kamgar, Phuong-Thu Pham, Gabriel Danovitch, Suphamai Bunnapradist.   

Abstract

BACKGROUND: Studies from older cohorts of kidney recipients have observed that recipients with sickle cell disease (SCD) have lower patient survival compared with age- and race-matched controls. We examined whether survival has improved among SCD recipients in the current era.
METHODS: Using Organ Procurement and Transplantation Network/United Network for Organ Sharing data, all black/African-American kidney recipients were stratified according to transplant year into an early (1988-99) and recent era (2000-11). Patient and allograft survival among SCD recipients and those with other diagnoses were compared (early era: SCD n = 67, others n = 20 694; recent era: SCD n = 106, others n = 34 428). A secondary-matched cohort analysis compared patient and allograft survival between SCD recipients matched to recipients with other diagnoses based on recipient and donor age, gender and donor type (deceased versus living).
RESULTS: Patient survival at 6 years was lower among SCD recipients in the early era compared with other diagnoses (55.7 versus 78.0%; P < 0.001). Six-year patient survival among sickle cell recipients improved in the recent era (69.8%; P versus early era = 0.04), although still trended toward lower survival compared with other diagnoses (80.0%; P = 0.07). Multivariate Cox proportional hazard models revealed an increased mortality risk with SCD in both eras [early: hazard ratio (HR) = 3.12; 95% confidence interval (CI): 2.15-4.54; recent: HR: 2.03; 95% CI: 1.31-3.16]. Patient survival among matched SCD recipients in the recent era was comparable to diabetic recipients (SCD: 73.1%, diabetes: 74.1%; P = 0.44).
CONCLUSIONS: Patient survival has improved among contemporary sickle cell recipients compared with an earlier cohort and is comparable to a matched cohort of diabetic kidney recipients. Appropriately selected SCD patients may receive kidney transplants with reasonable survival outcome.

Entities:  

Mesh:

Year:  2013        PMID: 23345624     DOI: 10.1093/ndt/gfs585

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

1.  Severe anemia early in life as a risk factor for sickle-cell kidney disease.

Authors:  Inmaculada Aban; Sujatha Baddam; Lee M Hilliard; Thomas H Howard; Daniel I Feig; Jeffrey D Lebensburger
Journal:  Blood       Date:  2016-12-05       Impact factor: 22.113

2.  Kidney biopsy findings in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study.

Authors:  Rima S Zahr; Marianne E Yee; Jack Weaver; Katherine Twombley; Raed Bou Matar; Diego Aviles; Rajasree Sreedharan; Michelle N Rheault; Rossana Malatesta-Muncher; Hillarey Stone; Tarak Srivastava; Gaurav Kapur; Poornima Baddi; Oded Volovelsky; Jonathan Pelletier; Rasheed Gbadegesin; Wacharee Seeherunvong; Hiren P Patel; Larry A Greenbaum
Journal:  Pediatr Nephrol       Date:  2019-04-03       Impact factor: 3.714

Review 3.  Management of sickle cell disease in the community.

Authors:  Valentine Brousse; Julie Makani; David C Rees
Journal:  BMJ       Date:  2014-03-10

Review 4.  Health Disparities in Kidney Transplantation for African Americans.

Authors:  Kimberly Harding; Tesfaye B Mersha; Phuong-Thu Pham; Amy D Waterman; Fern A Webb; Joseph A Vassalotti; Susanne B Nicholas
Journal:  Am J Nephrol       Date:  2017-08-05       Impact factor: 3.754

Review 5.  Chronic organ failure in adult sickle cell disease.

Authors:  Elliott Vichinsky
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.

Authors:  Hitomi Hosoya; Jeffrey Levine; Peter Abt; David Henry; David L Porter; Saar Gill
Journal:  Blood Adv       Date:  2018-03-13

7.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.

Authors:  Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa
Journal:  Blood Adv       Date:  2019-12-10

8.  Cardiac expression of HMOX1 and PGF in sickle cell mice and haem-treated wild type mice dominates organ expression profiles via Nrf2 (Nfe2l2).

Authors:  Oluwabukola T Gbotosho; Samit Ghosh; Maria G Kapetanaki; Yu Lin; Frances Weidert; Grant C Bullock; Solomon F Ofori-Acquah; Gregory J Kato
Journal:  Br J Haematol       Date:  2019-08-06       Impact factor: 6.998

9.  Liver Transplantation in Patients with Sickle Cell Disease in the United States.

Authors:  Rachel Hogen; Michelle Kim; Yelim Lee; Mary Lo; Navpreet Kaur; Jeff Kahn; Shefali Chopra; Yasir Qazi; Ashraf Sedra; Jim Kim; Lauren O'Brien; Yuri Genyk; Linda Sher; Juliet Emamaullee
Journal:  J Surg Res       Date:  2020-06-12       Impact factor: 2.192

Review 10.  How I treat the older adult with sickle cell disease.

Authors:  Swee Lay Thein; Jo Howard
Journal:  Blood       Date:  2018-09-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.